Gregory L. Weaver
EVP & CFO at Atossa Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Atossa Therapeutics Inc., 3 years.
Atossa Therapeutics Inc.
Director · Former EVP, CFO, & Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Altimmune Inc. | Grant or award | +1,753 | $2.41 | $4,232 |
| Apr 1, 2026 | Altimmune Inc. | Open-market purchase | +10,000 | $3.15 | $31,500 |
| Mar 6, 2026 | Altimmune Inc. | Open-market purchase | +5,000 | $3.54 | $17,700 |
| Nov 11, 2025 | Altimmune Inc. | Option exercise | +18,750 | — | — |
| Nov 11, 2025 | Altimmune Inc. | Shares withheld for tax | −5,672 | $4.28 | $24,276 |
| Mar 13, 2025 | Altimmune Inc. | Open-market purchase | +10,000 | $5.20 | $52,000 |
| Nov 15, 2023 | Atossa Therapeutics Inc. | Open-market sale | −50,000 | $0.65 | $32,500 |
| Jun 20, 2023 | Atossa Therapeutics Inc. | Open-market purchase | +50,000 | $0.97 | $48,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.